Hager Investment Management Services LLC Acquires Shares of 796 Becton, Dickinson and Company (NYSE:BDX)

Hager Investment Management Services LLC purchased a new position in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 796 shares of the medical instruments supplier’s stock, valued at approximately $181,000.

Other hedge funds have also recently modified their holdings of the company. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company during the third quarter valued at about $26,000. Ashton Thomas Securities LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter worth about $33,000. Tompkins Financial Corp lifted its position in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares in the last quarter. Sound Income Strategies LLC lifted its position in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new stake in Becton, Dickinson and Company during the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling

In other news, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the sale, the executive vice president now directly owns 14,217 shares in the company, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,844 shares of company stock worth $2,210,716 in the last 90 days. Insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Down 2.3 %

Becton, Dickinson and Company stock opened at $242.01 on Wednesday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The business has a fifty day moving average of $230.97 and a two-hundred day moving average of $233.94. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market cap of $70.18 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.80 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.42 EPS. On average, analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.72%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Piper Sandler upped their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.